- The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
-
Taki S, Tamai H, Ida Y, Shingaki N, Kawashima , Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2404722
- Gut Liver.
- 2018 Jan;12(1):86-93.
- doi: 10.5009/gnl17048
BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Guidelines for Management of Chronic Hepatitis C
-
Kim KA
- KMID: 2269065
- Korean J Med.
- 2015 Jun;88(6):623-629.
- doi: 10.3904/kjm.2015.88.6.623
Therapeutic options for patients with hepatitis C virus infection have evolved substantially with the advent of highly effective direct-acting antiviral agents (DAA). Guidelines for treatment of hepatitis C have changed... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advancement in the Treatment of Chronic Hepatitis C
-
Kim TH, Lee JS
- KMID: 2269300
- Korean J Med.
- 2014 May;86(5):563-569.
Currently, the most widely prescribed standard therapy for chronic hepatitis C consists of pegylated-interferon combined with ribavirin. Although the response rate to interferon-based treatments has improved since interferon monotherapy was... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
-
de Medeiros LPJ, Lima MB, Pires MM, Maciel AM, Medeiros R, Donadel MD, Pereira IM, Leão FM, Pires LE, Rzetelna H, Brandão-Mello CE
- KMID: 2413256
- Osong Public Health Res Perspect.
- 2018 Apr;9(2):50-58.
- doi: 10.24171/j.phrp.2018.9.2.03
OBJECTIVES: To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) +... -
- CITED
-
- Close
- SHARE
-
- Close
